IL17A CRITICALLY SHAPES THE TRANSCRIPTIONAL PROGRAM OF FIBROBLASTS IN PANCREATIC CANCER AND SWITCHES ON THEIR PRO-TUMORIGENIC FUNCTIONS by Mucciolo, G et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
IL17A CRITICALLY SHAPES THE TRANSCRIPTIONAL PROGRAM OF FIBROBLASTS IN PANCREATIC CANCER AND





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is a pre print version of the following article:






This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
Proc Natl Acad Sci U S A. 2019. doi: 10.1073/pnas.2020395118 
ovvero [Mucciolo et al., Feb 1;118(6), PNAS, 2021, pagg 1-9] 
The definitive version is available at: 









IL17A critically shapes the transcriptional program of fibroblasts in pancreatic 
cancer and switches on their pro-tumorigenic functions. 
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A hallmark of cancer, including pancreatic ductal adenocarcinoma (PDA), is a massive stromal and 
inflammatory reaction. Many efforts have, therefore, been made to identify the anti- or pro-tumoral 
role of cytokines and immune subpopulations dispersed within the stroma. In this study, we have 
investigated the role of IL17A and its effect on tumor fibroblasts and, consequently, on the tumor 
microenvironment. 
KPC mice that spontaneously developed PDA, due to the pancreas specific expression of Trp53R172H 
and KrasG12D, were crossed with IL17A knockout mice. KPC/IL17A-/- mice showed an extensive 
desmoplastic reaction, which did not impair a great immune infiltrate. Both macrophages, especially 
CD80+ and T cells, were more abundant at the earlier time point. Regarding T cells, a decrease in 
FoxP3+ cells and an increase in CD8+ T cells were observed in KPC/IL17A-/- mice compared to 
KPC/IL17A+/+ mice. Fibroblasts isolated from IL17A+/+ and IL17A-/- KPC mice revealed very 
different mRNA and protein profiles. IL17A-/- fibroblasts displayed the ability to restrain tumor cell 
invasion by producing factors involved in extracellular matrix remodeling and by increasing T cell 
recruitment. In particular, IL17A-/- fibroblasts produced higher levels of cytokines and chemokines 
favoring T helper 1 cell recruitment and activation, and lower levels of those recruiting 
myeloid/granulocytic immune cells. Single-cell quantitative PCR was performed with isolated 
fibroblasts and confirmed a very divergent profile of IL17A proficient and deficient cells. All these 
features can be ascribable to increased levels of IL17F observed in the sera of mice lacking IL17A, 
and to the higher expression of its cognate receptor (IL17RC) specifically in CAF IL17A-/-. In 
addition to the known effects on neoplastic cell transformation, the IL17 cytokine family uniquely 
affects fibroblasts, and represents a suitable candidate target for combinatorial immune-based 
therapies in PDA. 
 
Significance of this study 
	 4	
There is controversial data about the pro-tumoral role of pancreatic cancer stroma, and dissecting 
multiple aspects will help to develop effective tailored therapies. IL17A has been reported to 
accelerate the pancreatic acinar-ductal metaplasia, be important for maintaining stem-like cancer cells 
and recruit immunosuppressive granulocytes into the tumor. 
Here we unveil a novel relationship between IL17A and pancreatic stromal cells, which strongly 
modifies their gene and protein expression profiles. Ablation of IL17A, in fact, modifies the 
cytokines/factors released by tumor fibroblasts by limiting T cell immunosuppression. 




A histological hallmark of pancreatic ductal adenocarcinoma (PDA) is pronounced desmoplasia. This 
derives from pancreatic stellate cells (PSC) activated to proliferate and produce collagens, laminin, 
and fibronectin, which differentially shape the stroma(1). The stroma also harbors infiltrative 
macrophages and inflammatory cells with the potential to suppress anti-tumoral immune 
mechanisms(2). 
Although PDA is considered a “cold tumor” or “immune privileged site”, it engages the immune 
system from its inception. Initially, cells of the innate system, such as macrophages and mast cells, 
are mainly involved(3). However, even early on, cells of adaptive immunity, particularly T cells are 
also engaged(4). Higher levels of tumor-infiltrating CD4 and CD8 lymphocytes and dendritic cells 
positively correlate with longer survival after surgical resection(5). We have recently reported that 
PDA-infiltrating lymphocytes specifically recognize PDA-associated antigens, but are often impaired 
in their effector functions due to the presence of regulatory T (Treg) cells(6) and macrophages(7). 
Levels of T helper 17 (Th17) cells and IL17 were also found to be elevated in pancreatic immune-
infiltrates from humans as well as from mice (8), and their increase is Kras-dependent. 
Until recently, treatment was designed to either limit the inflammatory response or deplete the stroma 
to enhance drug delivery to the cancer cells, while disrupting deleterious stroma-cancer cell 
interactions. A lot of data seems to support this hypothesis, but further investigations are needed, as 
tumor-restraining and -promoting functions of stroma have been described(9). In pancreatic cancer, 
IL17, produced by classical ab but also gd T cells, neutrophils and myeloid cells, has been described 
involved in the acinar-ductal metaplasia and metastasis(10, 11), in the re-differentiation of pancreatic 
cancer cells in stem-like cells(12), and more recently in modulating neutrophil recruitment into 
pancreatic cancer with the consequence cytotoxic CD8 T cell exclusion(8). In addition, a Th2- and 
Th17-skewed response was associated with a paucity of dendritic cells (DC) that infiltrate PDA at an 
early stage of disease, and faster tumor progression(13). In this study, we investigated the role of 
IL17A in modulating PDA-associated stromal cells in a spontaneous mouse model that faithfully 
	 6	
recapitulates human PDA progression (KPC mice) crossed with IL17A knock-out mice. We observed 
a strong fibrotic reaction and matrix deposition in PDA from KPC/IL17A-/- mice, which paralleled 
higher infiltration of CD3+ T cells and, in particular, CD8+ T cells. The transcriptomic and secretome 
analysis of fibroblasts isolated from PDA arose in KPC/IL17A proficient or deficient mice revealed 
a different pattern of cytokine/chemokine production in the absence of IL17A, which suggests a shift 
from an immunosuppressive to an anti-tumoral microenvironment. Our results provide new insights 
into dissecting the role of IL17 family in PDA progression, which open the possibilities of designing 




The absence of IL17A increases the desmoplastic reaction at the tumor site. 
PDA patients and mice spontaneously developing PDA, namely KC and KPC mice(14), displayed a 
trend of increase of IL17A-secreting CD4 T cells, and significantly higher IL17A in the sera, 
compared to healthy non-tumor counterparts (SI Appendix, Table S1 and Fig. S1). In addition, in 
mice, the frequency of Th17 was higher in the first weeks of age (SI Appendix, Fig. S1B). The increase 
of IL17A is Kras-dependent, as was observed only in presence of mutated Kras and/or TP53 but not 
in age-matched mice carrying the Pdx-1-Cre recombinase alone (SI Appendix, Fig. S1C). The high 
levels of IL17A in mouse sera at the late stage of disease, despite the decrease in IL17A-producing 
cells in the blood, may reflect the high secretion of this cytokine by other cells, such as gd T cells 
(mainly producers), NKT cells, neutrophils and myeloid cells, which are dispersed into the tumor or 
lymphoid organs. These results prompted us to evaluate the progression of PDA in the absence of 
IL17A. 
KPC mice were bred with IL17A-/- mice(15) to create a spontaneous autochthonous mouse model of 
PDA developing in the genetic absence of IL17A. KPC/IL17A-/- mice showed a significantly 
prolonged survival compared to the proficient KPC mice (SI Appendix, Fig. S2A). However, when 
pancreatic tissues were histologically analyzed, no differences were observed in terms of percentage 
of tumors (SI Appendix, Fig. S2B and C). Analyzing the expression of the different receptors for the 
IL17 family members, PDA cells from KPC/IL17A-/- mice expressed more IL17RA, the common 
chain, but less IL17RC, which dimerizes with the IL17RA to bind homo- and hetero-dimers of IL17A 
and IL17F (SI Appendix, Fig. S2D). Notably, we observed higher levels of IL17F in the sera of 
KPC/IL17A-/- mice compared to the proficient KPC, but no differences were observed in the single 
mutated model KC (SI Appendix, Fig. S1E and F). Tumor cells from KPC/IL17A-/- mice also 
expressed less IL17RE, the ligand of which is IL17E or IL25 that shares less homology with the other 
members of the family, and more IL17RD the ligand of which is unknown, and has been suggested 
to bind IL17A but not IL17F (SI Appendix, Fig. S2D). Both IL17A-proficient and IL17A-deficient 
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PDA cells produce very little IL17F, if any (SI Appendix, Fig. S2E). These data suggest that tumor 
cells in the absence of IL17A have a decrease in the receptor chains binding IL17F, and may be less 
responsive to this cytokine, which concomitantly increases. When we histologically analyzed the 
tumors that arose in KPC IL17A-proficient and -deficient mice, KPC/IL17A-/- mice displayed a 
significantly higher percentage of fibrosis compared to IL17A-proficient mice at every time point 
(Fig 1A and B). Multiphoton confocal microscopy imaging by second harmonic generation (SHG) 
revealed a structurally different collagen texture in KPC/IL17A-/- mice compared to IL17A-proficient 
controls (Fig 1B lower panels). In particular, the absence of IL17A led to the formation of less 
compact, more fibrillar net-like structures around the tumor and in the peri-tumoral area, with a 
tendency of greater involvement of the tissue (collagen in yellow). Notably, as shown in the lower 
right panels, KPC/IL17A-/- mice also displayed a normal acinar area surrounded by intense fibrosis 
(Fig. 1B). In addition, analysis of SHG imaging revealed that the integrated density (referred to as 
intensity of signal due to collagen fiber thickness and/or accumulation), was higher in the 
KPC/IL17A+/+ tissues even in the presence of a similar total area of collagen occupation, which 
actually increased in KPC/IL17A-/- mice at 20 weeks of age (SI Appendix Fig. S3A and B). This was 
also supported by the average size of fibers, obtained by measuring the single dots in which the full 
collagen image, resulting from the detected SHG signal above the background threshold, being 
fragmented. This size was evidently higher in KPC/IL17A+/+ pancreas at a later stage (at 20 weeks) 
(SI Appendix Fig. S3C). These data also suggest a progressive increase of stiffness in the presence of 
IL17A, because of the accumulation and increasing thickening of the collagen structure, which is 
opposite to the more diffuse and less dense accumulation in pancreas in the absence of IL17A. 
Interestingly, PDA patients with high levels of IL17A in their sera (N = 10, SI Appendix Table S1) 
displayed wide and strengthened collagen fibers interspersed in the matrix and tumor cells similarly 
to KPC/IL17A+/+ mice. By contrast, PDA patients with low levels of IL17A (N = 10) displayed softer 
collagen fibers, as observed in KPC/IL17A-/- mice (Fig. 1C). To classify patients with high or low 
levels of IL17A in their sera, we established a cut-off level that corresponded to the average amount 
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of IL17A plus twice the SD detected in the sera of healthy subjects (55 pg/ml). Therefore, the absence 
of IL17A led to more extensive desmoplasia, but much less compact and fibrillar-like collagen 
texture. 
 
The absence of IL17A influences the anti-tumoral phenotype of fibroblasts. 
To evaluate the role of IL17A in influencing tumor fibroblasts, we isolated cancer-associated 
fibroblasts (CAFs) from KPC/IL17A+/+ and KPC/IL17A-/- mice, and analyzed for typical stromal cell 
markers and their responsiveness to recombinant IL17A (rIL17A) (SI Appendix, Fig. S4A-C). We 
also isolated normal fibroblasts (NF) from the pancreas of non-tumor-bearing IL17A-proficient and 
-deficient mice to compare as baseline, whilst remaining aware of the bias of stimulating all these 
cells toward a myofibroblastic phenotype(16) by culturing them on plastic supports. Due to the 
increased IL17F levels in the sera of tumor-bearing mice, we also evaluated the expression of all the 
members of the IL17R family and the production of IL17F from CAFs and NFs (SI Appendix, Fig. 
S4D and E). In the absence of the IL17A gene, the IL17R family was present at similar levels 
observed in IL17A-proficient CAFs and NFs, with the exception of IL17RB, which seemed absent or 
undetectable in all cells, and the IL17RC chain, which was significantly more expressed in 
CAFs/IL17A-/- compared to CAFs/IL17+/+, and compared to both IL17A-proficient and -deficient 
NFs (SI Appendix, Fig. S4D). As expected, all CAFs and NFs produced little IL17F (SI Appendix, 
Fig. S4E). These data suggest that CAFs could be more responsive to IL17F in the absence of IL17A, 
due to the higher expression of its receptor. 
mRNA was purified to evaluate gene expression by qPCR, with a customized plate having 87 unique 
genes related to fibrosis, and supernatants were collected to evaluate the secretion of more than 100 
cytokines/chemokines and soluble factors. SI Appendix Fig. S5A and B shows two heat maps obtained 
from the unsupervised hierarchical analysis of RNA, and protein expressions of IL17A+/+ CAFs, 
IL17A-/- CAFs and IL17A-/- CAFs stimulated with rIL17A. The absence of IL17A strongly modulated 
65 transcripts (SI Appendix Fig. S5A and Fig. 1D); in particular, 15 were down-regulated (<0.5) and 
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50 were up-regulated (>2) in IL17A-/- CAFs compared to IL17A+/+ CAFs. Genes up-regulated by 
more than 50-fold included collagen type I (Col1a1), metalloproteases (Mmp2, Mmp9), fibroblast 
growth factor (Fgf)-2, hepatocyte growth factor (Hgf), insulin growth factor (Igf)-1, chemokine 
Cxcl10, Cxcl12 and Ccl5, and interferon (Ifn)-g. The propensity of IL17A-/- CAFs to reshape the 
matrix was also suggested by the up-regulation of transcripts of tissue inhibitor metalloproteases 
(Timp)-3 (25-fold), Serpin1 (13.4-fold) and plasminogen activators, namely Plau and Plat (6.3- and 
6.7–fold, respectively). Activation of the Tgfb pathway was confirmed by the up-regulation of its 
receptor (Tgfbr2) and Smad2, 3 and 4 transcripts (from 2- to 10-fold), as well as TGFb-induced genes 
(e.g. Ctgf, Col1A1, Cxcl12), although the Tgfb transcript itself was down-regulated (0.5-fold). 
Noteworthy, many cytokine transcripts were also upregulated: Il12a and Il12b, Il1b, Il6, Ifn-g, 
interferon regulatory factor (Irf)-1, and tumor necrosis factor (Tnf)-a (Fig. 1D). Notably, Ifn-g, Il12 
and Il1b, were not amplified at all in any IL17A+/+ CAFs. Ingenuity Pathway Analysis (IPA) by using 
genes significantly up- and down-modulated suggested that one of the top upstream regulators of 
genes modulated in the absence of IL17A (besides TGFb) was indeed IFN-g (p-value = 1.22 x 10-34) 
(Fig. 1E). IPA also confirmed activation of the Th1 pathway (Z score = 1.67, p-value = 4.8x10-6), 
NFkB (Z score = 1.63, p-value = 2.7x10-5), DC maturation (Z score = 1.41, p-value = 0.3x10-8) and 
the inhibition of the Th2 pathway (Z score = -2, p-value = 1.9x10-4) in the absence of IL17A. 
Interestingly, although clustered together by the unsupervised hierarchical analysis, NFs from IL17A-
/- mice displayed 23 up-regulated transcripts and 13 down-regulated transcripts compared to IL17A-
proficient NFs (SI Appendix, Fig. S5C). In addition, fold-change of transcripts related to Th1 
recruitment and activation, matrix remodeling and cell growth, which was increased in IL17A-/- CAFs 
compared to IL17A+/+ CAFs, was also higher in IL17A-/- CAFs compared to IL17A-/- NFs. In parallel, 
fold-change of transcripts related to myeloid/granulocyte recruitment and activation, which was lower 
in IL17A-/- CAFs compared to IL17A+/+ CAFs, was also reduced in IL17A-/- CAFs versus IL17A-/- 
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NFs (SI Appendix, Fig. S5E). These data suggest that the absence of IL17A does not substantially 
influence normal fibroblasts, whereas it critically affects CAF functions. 
Adding rIL17A to IL17A-/- CAFs significantly modulated 45 transcripts, specifically, 29 were 
downregulated and 16 were upregulated (SI Appendix Fig. S5A and Fig. 1D). Almost all the highly 
upregulated transcripts induced by the absence of IL17A were downregulated by adding rIL17A, with 
the exception of FgfR2 and Igf-2, which were further increased. All genes related to matrix 
remodeling were down-modulated, along with transcripts for Th1 cytokines, namely Il12a, Il12b, Ifn-
g and Tnf-a (neither Il12a nor b was amplified, and Ifn-g and Tnf-a  were down-regulated by 0.31- 
and 0.23-fold, respectively). Conversely, transcripts for granulocyte and monocyte-colony 
stimulating factor (Gm-csf) and granulocyte-colony stimulating factor (G-csf), and for the chemokine 
Cxcl1 recruiting myeloid and granulocyte cells, were restored (3.6-, 4- and 11-fold, respectively) (Fig. 
1D). 
Cytokine arrays were performed with supernatants from three different CAF bulks of each genotype, 
and from three IL17A-/- CAF bulks stimulated with rIL17A. A total of 57 proteins among the 144 
tested were affected by ±30% due to the absence of IL17A; 32 proteins were down-regulated and 25 
were up-regulated (Fig. 1D and SI Appendix Fig. S5B). Most of the upregulated proteins were 
chemokines attracting dendritic cells (e.g. CCL9; 2.35-fold) and T cells. Among them, CXCL9, 
CXCL12 and CCL5 were the most upregulated, increasing by about 1.9-, 1.4- and 4.5-fold, 
respectively. Notably, IL12 was upregulated by 70% in the supernatants of IL17A-/- CAFs, while 
Pentraxin3 and osteoprotegerin, which are usually regulated by TNF-a, were upregulated by about 
30%. Interestingly, all factors mobilizing and differentiating granulocyte and myeloid precursors 
(GM-CSF, G-CSF, M-CSF and Flt3) were downregulated in the absence of IL17A, whereas the SCF 
(KITLG) protein, normally produced by fibroblasts and endothelial cells and very similar to Flt3, but 
with the specific ability to affect mast cells, was upregulated by 2-fold (Fig. 1D). Insulin growth 
factor binding protein (IGFBP)-6 was the most upregulated protein (by 87-fold); IGFBP-6 binds IGFs 
with a higher affinity to IGF-2 than IGF-1, thus acting as a negative regulator(17) (Fig. 1D). Cytokine 
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array analysis with supernatants from both IL17A-proficient and deficient NFs revealed fewer 
differences between the two normal fibroblasts compared to that highlighted by the transcriptome 
analysis (SI Appendix Fig. S5D). Again, however, fold-changes of proteins related to Th1 recruitment 
and activation, which were increased in IL17A-/- CAFs compared to IL17A+/+ CAFs, were also higher 
in IL17A-/- CAFs compared to IL17A-/- NFs. In parallel, fold-changes of proteins related to the 
myeloid/granulocyte recruitment and activation, which were lower in IL17A-/- CAFs compared to 
IL17A+/+ CAFs, were also decreased in IL17A-/- CAFs versus IL17A-/- NFs (SI Appendix, Fig. S5E). 
Adding rIL17A to IL17A-/- CAFs resulted in the modulation of 68 proteins; 40 proteins were 
downregulated and 28 were upregulated. Notably, most of the proteins were inversely regulated by 
the presence of rIL17A, as highlighted by the heat map (Fig. 1D and SI Appendix Fig. S5B). 
We then investigated a PDA cohort in The Cancer Genome Atlas for genes related to the Th1 response 
and myeloid and granulocyte cell recruitment based on those enhanced or down-regulated in the 
absence of IL17A, as reported in Fig. 1D. The first group of genes, related to Th1 responses and T 
cell movement, were amplified or transcripts were enhanced in PDA patients with a better overall 
survival (Fig. 1F left panel). Conversely, genes related to granulocyte/monocyte movement and cell-
matrix interaction, which were significantly decreased in the absence of IL17A, were mutated, or 
transcripts were diminished in patients with a better overall survival (Fig. 1F, right panel). 
Overall, CAFs from IL17A-/- mice seemed more prone to matrix remodeling, favoring T cell 
recruitment, which, thanks to the cytokines released, namely CCL5, IL12 and IFN-g, may be skewed 
to a Th1 phenotype and expand CD8 T cells. 
 
IL17A affects fibroblast clustering based on transcriptional activity. 
To further characterize CAF populations, we performed a single cell qPCR analysis with CAF bulks 
from KPC/IL17A-/- or KPC/IL17A+/+ tumors. Despite the bias of performing a qPCR for 96 chosen 
genes, IL17A-proficient and -deficient CAFs clearly clustered into two different populations with 45 
genes being differentially expressed between the two genotypes (Fig. 2A and B and SI Appendix Table 
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S5), mostly confirming previous results. Bioinformatics analysis also revealed that both CAF 
genotypes clustered into two different subpopulations (cluster 0 and 3 for IL17A+/+ and 1 and 2 for 
IL17A-/-; Fig. 2A and B). Of the 45 differentially expressed genes, five genes were only statistically 
different in cluster 0 vs 3 but not in cluster 1 vs 2; ten genes were statistically different in cluster 1 vs 
2 but not 0 vs 3, and four genes were differentially expressed in both IL17A+/+ and IL17A-/- clusters 
(Fig. 2C). A total of 37 genes were not significantly different in IL17A-/- vs IL17A+/+ CAFs, but nine 
of them were differently expressed in clusters regardless of the presence of IL17A; nine were 
differentially clustering IL17A-/- CAFs, while only two were differentially clustering IL17A-
proficient CAFs (Fig. 2C). Notably, we observed that only IL17A-/- CAFs strongly expressed Cd34 
gene suggesting a hematopoietic origin, but they also expressed high levels of Acta2, Postn and 
Pdgfrb along with Col1a1 and Col5a2, usually expressed by fibroblasts (SI Appendix Table S5). 
 
The absence of IL17A affects PDA cellular infiltrate. 
To evaluate the presence of activated fibroblasts, macrophages and T cells, pancreatic tissues were 
analyzed by immunohistochemistry (IHC). In KPC mice, the absence of IL17A led to a huge increase 
in inter-dispersed aSMA+ cells and all around the tumor area, especially when invasive PDA was 
well established (Fig. 2D). There were more macrophages, evaluated as F4/80+ cells, in KPC/IL17A-
/- mice at 12 weeks of age (first time point analyzed), but they reached a similar score at later time 
points compared to the proficient counterparts (Fig. 2E). Interestingly, among macrophages, CD80+ 
cells were significantly more abundant in KPC/IL17A-/- than in KPC/IL17A+/+ tumors, while no 
significant changes were observed for the presence of CD163+ cells (SI Appendix, Fig. S6). Notably, 
we observed many more T cells (CD3+) in KPC/IL17A-/- mice at earlier time points, but not at 20 
weeks of age, because CD3+ levels in KPC/IL17A+/+ mice increased to similar levels (Fig. 2F). 
However, among these, FoxP3+ T cells significantly decreased in KPC/IL17A-/- mice when tumors 
were well-established compared to the proficient mice, despite being more abundant at early stages 
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(Fig. 2G), and CD8+ T cells were more numerous in KPC/IL17A-/- than in KPC/IL17A+/+ mice at all 
time points (Fig. 2H). 
Overall, even in the presence of greater fibrosis, the absence of IL17A increased PDA immune cell 
infiltration by inflammatory-activated macrophages and effector CD4 and CD8 T cells. 
 
The IL17A-dependent fibroblast phenotype shapes the anti-tumor T cell response and 
PDA cell invasion. 
To assess if treatment with an anti-IL17A antibody (Ab) recapitulated features, in terms of gene 
expression and immune cell recruitment, observed in CAFs and tumors from KPC/IL17A-/- mice, 
C57/Bl6 mice were orthotopically injected with syngeneic PDA cells, and left untreated or treated 
with an anti-IL17A Ab biweekly. Treatment only slightly decreased the weight of tumors evaluated 
at 28 days after cell challenge (SI Appendix, Fig. S7A), probably due to the high rate of tumor growth 
and aggressiveness. No differences were observed in fibrosis or aSMA+ cells for the surgical approach 
in the orthotopic injection (SI Appendix Fig. S7B). However, analyses by IHC of the immune infiltrate 
revealed a trend of increase in CD3+ cells, and a parallel decrease in FoxP3+ cells in mice treated with 
the anti-IL17A Ab, compared to control mice (SI Appendix Fig. S7C and D). mRNA extracted from 
paraffin-embedded pancreatic sections from KPC/IL17A+/+, KPC/IL17A-/- and from mice injected 
orthotopically and left untreated or treated with the anti-IL17A Ab, were analyzed by qPCR (Fig. 3A 
and B). The absence of IL17A in KPC mice strongly upregulated transcripts associated with T cell 
activation after antigen recognition, namely B2m, Nfatc and Calm3, and with the effector T cell 
phenotype, such as Gzmb, Il18, Fasl, Cd8, Jak1 and Ccr5. Notably, genes antagonizing the Th1 
response such as Rorc, Tgfb1, Tlsp and Il4 were downregulated by more than 100-fold (Fig. 3A). The 
increased transcripts of Gzmb, Stat1, Fasl and B2m also confirmed the “interferon signature” 
observed by analyzing the CAF transcriptome and secretome.  
Notably, the anti-IL17A Ab treatment of mice orthotopically injected with syngeneic PDA cells 
demonstrated a transcript regulation pattern that suggested a microenvironment similar to that 
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observed in KPC/IL17A-/- mice (Fig. 3B). Indeed, the analysis of mRNA extracted from paraffin-
embedded pancreatic sections revealed that stromal (Cd36, Postn, Col1a1, aSma), T cell 
chemoattracting (Cxcl10, Cxcl11, Ccl5 and Ccr5) and T cell activation (Cd8, Nfkb, Nfatc, Gzmb) 
related genes were significantly upregulated compared to those evaluated in untreated mice (Fig. 3B). 
To assess the role of IL17A-stimulated CAFs in modulating tumor cell behavior we cultured PDA 
cells with rIL17A or supernatants from IL17A-/- CAFs. Cell viability was not affected at all by the 
addition of rIL17A (SI Appendix Fig. S8A), while it only directly affected cell invasion after 24 h (SI 
Appendix Fig. S8B). Supernatants collected from all CAFs induced a similar rate of invasion after 24 
h of culture, while IL17A+/+ CAFs significantly increased the invasion by PDA compared to that from 
IL17A-/- CAFs and from IL17A-/- CAFs stimulated with rIL17A after 48 h, which, however, only 
induced a slight increase in the PDA invasion ability (SI Appendix, Fig. S8C). Evaluating some 
epithelial-to-mesenchymal transition (EMT) genes revealed the up-regulation of Zeb and Snail by 
rIL17A alone (1 ng and 10 ng/ml, respectively) and of Zeb1, Slug and vimentin by the addition of 
supernatants from IL17A-/- CAFs. Of note, the stimulation of IL17A-/- CAFs with rIL17A made them 
release some factors, which stimulated upregulation of all the EMT transcripts evaluated (SI 
Appendix, Fig. S8D). These results may partially explain the lower number of metastasis that we 
observed in KPC/IL17A-deficient mice, at later time points, and especially in the lungs (SI Appendix 
Fig. S8E). 
Overall, these results supported the hypothesis that the absence of IL17A increases both fibrosis-
associated genes, but also inflammatory-activated T cells. In addition, the absence of IL17A modifies 
CAFs for restraining tumor cell invasion. 
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Discussion 
The present study was aimed at characterizing the role of IL17A in modulating fibroblasts associated 
with PDA, and consequently their role in supporting or suppressing the anti-tumor response. The 
most remarkable histological feature in our spontaneous mouse model of PDA lacking the IL17A 
gene was enhanced fibrotic reaction. This first observation is divergent from that observed after 
treatment with the combination of anti-IL17A, anti-IL17F and IL17RA antibodies(10). Of interest, 
IL17F increased in the absence of IL17A, and IL17RC was upregulated specifically on CAFs, but 
not PDA cells. This suggests that in the absence of IL17A, the interaction between IL17F and its 
receptor plays a role in differently modulating the tumor environment. Notably, this enhanced fibrosis 
seemed to have a “tumor-restrainer” function. Some stromal constituents, indeed, act to contain rather 
than promote tumor progression(18, 19), and recent studies have started to define the complex stromal 
population in greater depth(20, 21). Clinical studies employing patient biopsies also correlated the 
extent of desmoplasia, after stroma and collagen quantification, with a better prognosis(22–24). More 
recently, it has been observed that the lower density of tumor stroma corresponds to a higher 
cellularity in liver metastasis, which correlates with lower patient survival. In addition, the reduction 
of matrix in a PDA orthotopic mouse model through an anti-LOXL2 antibody decreased tissue 
stiffness, but increased tumor growth, and reduced gemcitabine responsiveness that negatively 
impacted on mouse survival(25). This highlights the need to systematically determine the effects of 
many soluble factors released by immune cells as well tumor cells on the activation of PDA stroma 
to improve the development of effective and “tailored” therapeutic strategies. 
KPC/IL17A-/- mice displayed a less suppressive tumor microenvironment than that described for wild 
type mice(26); they were infiltrated to a much greater extent by CD3+, CD8+ and F4/80+ cells, with a 
significant increase in CD80+ macrophages, despite the presence of abundant fibrosis and stroma, 
indicating an attempt by the immune system to mount an anti-tumor response. Acute and chronic 
pancreatitis in mice lacking NFkB essential modulator (NEMO) showed a similar pattern of 
inflammation and fibrosis observed in KPC/IL17A-/-(27). It appears that the absence of certain 
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immune modulators, such as NEMO or IL17A, which also signal through NFkB, similarly increases 
the inflammatory response and exacerbates the fibrotic reaction in PDA. 
Unsupervised hierarchical analysis of fibroblast transcript and secretome confirmed the similar origin 
of fibroblasts, clustering together CAFs and NFs. However, although many cytokines and 
chemokines have been described to be commonly secreted by normal activated fibroblasts and 
CAFs(28), the increase of T cell-recruiting chemokines and Th1-skewing cytokines in IL17A-/- CAFs 
suggests their role in promoting an effector inflammatory response, similar to that known to be 
induced after infection or cell injury. In tumors, this type of reaction may correspond to an anti-tumor 
immune response (Fig. 4). This hypothesis was confirmed by the Th1 and cytotoxic signature 
observed in tumors from KPC/IL17A-/- and anti-IL17A-treated mice compared to their proficient 
counterparts, as well as the activation of an “interferon signature”, as revealed by Gzmb, Fasl, Stat1 
and B2m mRNA upregulation. The interferon signature and cytotoxic lymphocytes, in fact, are 
usually associated with a good cancer prognosis and can predict the response to immune check-point 
inhibitory therapies(29). 
Single cell analysis of IL17A+/+ and IL17A-/- CAFs confirmed the presence of two main 
subpopulations regardless of the presence or absence of IL17A, but more than half of the amplified 
genes were significantly different in IL17A-/- compared to proficient CAFs. Notably, the expression 
of Cd34 by IL17A-/- cells only suggested the hematopoietic origin of these fibroblasts, which, 
however, also expressed higher or similar levels of genes usually associated with a fibroblast 
phenotype (Acta2, Postn, Pdgfrb, Col1a1, Col5, Col4a1 and Col4a2). Of note, the loss of CD34 on 
stromal cells has been associated with the increased ability of breast cancer cells to invade 
surrounding tissues and metastasize(30), and has been defined as an independent prognostic factor in 
non-small cell lung cancer stage I-III(31). Interestingly, IL17A+/+ CAFs also highly expressed Anxa6 
and Areg, which were almost absent in IL17A-/- CAFs. The former was demonstrated to be typical of 
stromal cells promoting tumors and metastasis(20), and the latter is an important factor supporting 
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tumor cells by increasing their survival, neoangiogenesis and recruitment of protumoral 
macrophages(32, 33). 
Another set of genes, significantly modulated by the absence of IL17A, are those involved in 
extracellular matrix remodeling, and indirectly related to cellular invasion, which have been 
implicated in PDA progression and resistance to treatment. In line with this data, we observed a 
different structure and size of collagen fibers in PDA from IL17A-/- mice compared to those in 
proficient mice. In the absence of IL17A, collagen deposition is more orientated to form soft nests 
rather than compact capsules around tumor cells, as demonstrated by SHG microscopy and 
quantitative analysis of the integrated density. Collagen fiber organization correlates with the ability 
of tumor cells to invade, as straight aligned fibers represent paths on which cancer cells can move, 
and also influences the epithelial-to-mesenchymal transition (EMT)(34, 35). Therefore, our results 
highlight the formation of two functionally different scaffolds; the first, softer matrix allows immune 
cell accumulation and lowers the induction of tumor cell motility and, possibly, maintains better 
differentiation; the second, in IL17A-proficient mice, allows matrix stiffening with consequent 
hindrance of immune cell infiltration, but stimulates EMT, which promotes cell mobilization, 
infiltration and spreading(36). 
Notably, some markers associated with PSC were more upregulated in IL17A-/- CAFs compared to 
IL17A+/+ CAFs (SI Appendix Fig. S4B). This suggests a persistence or a tendency to renew these cells 
rather than their conversion into pro-tumoral myofibroblasts(16, 20). A link with the persistence of 
activated fibroblasts and PSC could be represented by the massive increase in IGFBP-6 secretion. 
IGFBP-6 overexpression is protective for fibroblasts as it markedly delays the onset of 
senescence(37). In addition, IGFBP-6 acts as a dominant negative regulator of the IGF pathway; 
therefore, in IL17A-/- mice, where IGFBP-6 is upregulated, it could prevent pro-tumorigenic effects 
of both IGF1 and IGF2(38), which are abundantly secreted by both stromal and tumor cells. By 
blocking this signaling, a fully human monoclonal antibody (IgG1) against IGF-1R, inhibits the 
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growth of pancreatic as well breast and renal tumors, and induces a marked increase in apoptotic 
tumor cells(39). 
In conclusion, we demonstrate here that IL17A differently modulates stromal cells and creates a 
suppressive environment by recruiting granulocytes and myeloid suppressive cells, which - in turn - 
induces Treg cells and reduces the attempt of an efficient cellular anti-tumor response. The absence 
of IL17A, instead, did not limit stroma in PDA, but converted the immunosuppressive environment 
into an anti-tumoral one, as schematically represented in Fig. 4. Cytokines and chemokines produced 
by CAFs in the absence of IL17A favor the recruitment of Th1 and cytotoxic CD8+ T cells, and limit 
the presence of suppressive myeloid cells and Treg. Our findings emphasize the importance of deep 
analyzing the tumor microenvironment to avoid the general elimination of stroma and fibroblasts, 
rather than modifying their function. Overall, identifying a novel relationship between IL17A and the 
stroma also provides a proof-of-concept for its inhibition in combined therapeutic strategies.  
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Materials and Methods 
Human samples. Human PBMC and sera were isolated from PDA patients enrolled in the study 
known as PANIN (SI Appendix Table S1), previous informed consent was obtained, and the study 
was approved by the Ethical Committee (N. 2CEI/587) of the Città della Salute e della Scienza di 
Torino, Italy and of the Policlinico Hospital, Verona, Italy. Blood from healthy donors was obtained 
by the local Blood Bank. 
 
ELISA. Human and mouse IL17A, and mouse IL17F were quantified in sera from healthy subjects, 
PDA patients and/ IL17A-proficient and -deficient or KC, KPC and Pdx-1-Cre mice (dilution 1:50 
for IL17A or pure for mIL17F), by means of an ELISA assay, following the manufacturer’s 
instructions (both from Biolegend by Prodotti Gianni).  
 
Immunophenotyping. Detailed procedures of immunophenotyping can be found in the SI 
Appendix.  
 
Mice. Generation and characterization of mice carrying double-mutated KrasG12D and Trp53R172H 
(KPC) under the endogenous promoter and flanked by Lox-STOP-Lox cassettes have been previously 
described(14). Mice were crossed with IL17A KO mice (kindly provided from Dr. Yoichiro Iwakura, 
University of Tokyo, Japan) to generate KPC/IL17A-/-. Mice were screened by PCR using tail DNA 
amplified by specific primers to Lox-P cassette flanking Kras and WT Kras genes, Lox-P cassette 
flanking Trp53 mutated and WT Trp53 and Cre recombinase genes (14). For IL17A-/- mouse 
genotyping see SI Appendix. 
 
Multiphoton Confocal Microscopy for Second Harmonic Generation (SHG) Imaging. 
All observations were performed at the 1- and 2-photon confocal microscopy at the facility of the 
Department of Biomathematics of the Institute of Physiology, Czech Academy of Sciences, using a 
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Leica TCSSP2 AOBS confocal laser scanning microscope (Leica, Wetzlar, GE) based on the Leica 
DM IRE2 inverted microscope, and equipped with an argon laser (40). For more details about the 
analysis and relative quantification see SI Appendix. 
 
Cell lines and CAF isolation. Mouse PDA cell lines, derived from a KPC/IL17A-/- mouse at 20 
weeks of age and a KPC/IL17A+/+ mouse at 18 weeks of age, and fibroblasts - isolated as described 
below - were cultured in DMEM supplemented with 20 mM glutamine, 2% or 10% FBS, and 
gentamycin (40 µg/ml; Fisiopharma, Milan, Italy). All in vitro cultures were performed at 37°C in a 
humidified 5% CO2 atmosphere. 
Mouse CAFs were isolated from KPC/IL17A+/+ and KPC/IL17A-/- mice with palpable PDA (28-20 
weeks of age), and from non-tumor bearing IL17A+/+ and IL17A-/- mice. Fibroblasts were isolated 
from tumoral and normal pancreas using a combination of outgrowth and clonal isolation after 
mechanical and enzymatic dissociation. See detailed procedures in SI Appendix. For some 
experiments, PDA cells and CAFs isolated from KPC/IL17A-/- mice were stimulated in the presence 
or absence of different concentrations of mouse rIL17A (1, 10 and 100 ng/ml; Abnova), and 
supernatants and cell pellets were collected and frozen until use. 
 
Cytokine array and quantitative Real-Time PCR. Cytokines, chemokines, metalloproteases 
and growth factors were evaluated in the supernatants from CAFs obtained from KPC/IL17A+/+ and 
KPC/IL17A-/- mice, and NFs from non-tumor bearing IL17A+/+ and IL17A-/- mice with the mouse 
cytokine array C2000 (RayBiotech by Prodotti Gianni), which evaluates 144 factors, by following 
the manufacturer’s instructions. For more details, see SI Appendix.  
RNA from fibroblasts was obtained after lysis of frozen cell pellets using Nucleozol, or by processing 
paraffin-embedded tissues with the PureLink FFPE Total RNA isolation kit following the 
manufacturer’s instructions (Invitrogen-ThermoFisher). iScript reverse transcription-kit (BioRad) 
was used to produce cDNA from 1µg of RNA, following the manufacturer’s instructions. The qRT-
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PCR reaction was performed using SYBR Green mix (Applied Biosystems by Thermo), and specific 
pairs of primers, or customized SYBR plates with unique 87 genes related to pancreatic fibrosis or T 
and B cell activation (SI Appendix and Table S2 and S3), and the SsoAdvance Universal SYBR green 
Supermix (both from BioRad) with the iQ96 machine or CFX1000 (BioRad). Gene expression was 
normalized to Gapdh. 
 
Single-cell quantitative Real-Time PCR. Single-cell Real-Time qPCR was performed using the 
C1 Single-Cell Auto Prep System in tandem with the BioMark HD System (Fluidigm Corporation, 
Markham, ON, Canada), in the facility of the Campbell Family Institute for Breast Cancer Research 
(Toronto, Canada). Details and analyzed genes are listed in SI Appendix and Table S4. 
 
Data and Single-cell qPCR analysis.  
Genesis software (https://genome.tugraz.at/genesisclient/genesisclient_description.shtml; BG-IKD 
Software) was used to perform complete analysis of qPCR and cytokine array data; values were auto-
scaled and the Pearson correlation was applied as the basis for distance measurement. Upstream 
regulator analysis was performed using the Ingenuity Pathway Analysis software (IPA; Ingenuity 
Systems, Redwood City, California). Genes and proteins to be differentially expressed in CAFs from 
KPC/IL17A-/-, compared to both CAFs from KPC/IL17A+/+ and KPC/IL17A-/- plus rIL17A, were 
imported for IPA analysis. Fold changes in KPC/IL17A-/- gene expression relative to KPC/IL17A+/+ 
CAFs were measured. Significance was determined using the right-tailed Fisher exact test. 
Seurat(41) was used to perform clustering and t-SNE dimensional reduction(42) of the single-cell 
expression data. The analysis was limited to genes expressed in at least three cells and cells expressing 
at least ten genes. This filter resulted in 358 cells and 82 genes being included in the analysis. Cluster 
markers and genes differentially expressed between the two genotypes were identified with a Mann-
Whitney U test with Bonferroni correction for multiple testing. 
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Histology and Immunohistochemistry. Detailed methods of immunohistochemical analysis of 
CD3, CD8, CD80, CD163, F4/80, αSMA and FoxP3 can be found in the SI Appendix. The presence 
of positive cells was defined as absent (score 0.2), scarce (score 0.4), moderate (score 0.6), strong 
(score 0.8), and huge (score 1) on sections decorated with the different antibodies. 
 
MTT and Matrigel-coated Transwell invasion assay. Cell survival was assessed by the MTT 
assay. PDA cells were seeded in a 96-well plate at 1.5x103 cells/well, and 20 μl of 5 mg/ml MTT 
solution (Sigma-Aldrich) was added to each well, and incubated at 37°C for a further 4 h every 24 h. 
Plates were centrifuged for 10 min at room temperature and medium was removed. The insoluble 
formazan product was dissolved in 200 μl of dimethyl sulfoxide (Sigma-Aldrich) for 10 min at room 
temperature on a platform shaker. Optical density values were measured at 570 nm with a microplate 
reader (NIVO, PerkinElmer). 
PDA cells seeded in triplicate on top of Matrigel-coated trans-wells were cultured with conditioned 
medium from unstimulated IL17A+/+ or IL17A-/- CAFs or IL17A-/- CAFs stimulated with rIL17A 
(10ng/ml). After 48 h, cells were fixed with methanol, stained with methylene blue and dissolved in 
5% acetic acid on a rotator for 15 min. A total of 100 μl of eluted cells were read at 570 nm wavelength 
with a microplate reader (NIVO, PerkinElmer). 
 
Statistical analysis. The student's t-test, two-way ANOVA, Mann Whitney test and Chi-square 
test were used to evaluate the differences in all the experiments as indicated, with the exception of 
single-cell analysis, which is described separately above. All tests were performed with GraphPad 
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Figure 1. IL17A affects fibrotic reactions in pancreatic cancer and differently shapes stroma. 
(A) Tumor pancreatic fibrosis quantification in KPC/IL17A+/+ (white floating bars) and KPC/IL17A-
/- (grey floating bars) mice. Each symbol corresponds to a single mouse analyzed with ImageJ (N = 
5-8 mice/group), and min to max values are represented. *P < 0.05 and ***P < 0.0001 represent 
significant differences in the IL17A-deficient mice compared to the IL17A-proficient mice. (B) 
Representative pictures of PicroSirius Red staining (upper panels) and of SHG microscopy analysis 
(lower panels) of pancreatic tissues from KPC/IL17A+/+ and KPC/IL17A-/- mice at the indicated age 
(N = 5-8 mice/group). The same areas were recorded in transmission light for PricoSirius Red staining 
and with the two-photon microscope for SHG, and collagen fibers are represented in yellow. Arrows 
indicate more dispersed and less compact collagen fibers, and arrowheads indicate straight and tight 
collagen fibers. Scale bar represents 75 µm. (C) Representative pictures of PicroSirius Red staining 
of pancreatic tissues from patients with high (left panels) and low (right panels) levels of serum 
IL17A. Magnification at 40X points out the differences in fibrillar structure. Scale bars represent 150 
µm and 50 µm respectively at 10X and 40X magnification. (D) A close-up view of specific genes 
and proteins differentially expressed in the absence of IL17A. The most relevant factors related to 
myeloid/granulocyte recruitment and activation (upper left), Th1 recruitment and activation (lower 
left), matrix remodeling (upper right) and cell growth (lower right) are grouped into four blocks. The 
color code maps represent the fold-change in IL17A-/- CAFs versus IL17A+/+ CAFs and in IL17A-/- 
CAFs stimulated with rIL17A (10 ng/ml) versus IL17A-/- CAFs, as indicated by each closed block 
(N=3 CAF bulk each). (E) Top upstream regulators predicted by IPA to be activated in the absence 
of IL17A. (F) Kaplan-Meier curves comparing survival of PDA patients from TCGA interrogation 
about genes found upregulated (Th1 response) or down-modulated (myeloid/granulocyte 
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Figure 2. Fibroblast clustering and differential immune infiltrate in the presence and absence 
of IL17A. (A) Unsupervised hierarchical clustering analysis of single-cell qPCR data. The color code 
map represents gene expression after the logarithmic normalization performed by Seurat. (B) 
Dimensional reduction using t-SNE: Cells are colored by genotype (upper plot) and by the four 
clusters found by Seurat (lower plot). (C) Venn diagram of genes differentially expressed between 
genotypes, between cluster 0 and cluster 3, and between cluster 1 and cluster 2. Alpha-SMA (D), 
F4/80 (E), CD3 (F), CD8 (G) and FoxP3 (H) quantification (upper panels) in pancreatic tumor tissues 
from KPC/IL17A+/+ mice (white floating bars) and KPC/IL17A-/- mice (grey floating bars). Each 
symbol corresponds to a single mouse, and min to max values are represented. *P < 0.05 and *** P 
< 0.0001 represent significant differences in the IL17A-deficient mice compared to the IL17A-
proficient mice; §§ P < 0.001 and §§§ P < 0.0001 represent differences in the same genotype group 
of mice compared to 12-week old mice. Middle and lower panels: IHC representative pictures of the 
above five markers, respectively, with tissues from KPC/IL17A+/+ and KPC/IL17A-/- mice at 12 
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Figure 3. IL17A-shaped fibroblasts impair the anti-tumor response. mRNA was isolated from 
tumor paraffin-embedded tissues from both KPC/IL17A+/+ and KPC/IL17A-/- mice (N = 3) (A) and 
from WT mice orthotopically injected with syngeneic PDA cells and untreated or treated with anti-
IL17A antibody (N = 5) (B) and analyzed by custom arrays for qPCR. Gapdh was used as a reference 
gene. The graph represents the mean fold-change of the indicated genes in KPC/IL17A-/- mice 
compared to KPC/IL17A+/+ mice or in anti-IL17A treated mice compared to untreated mice. Fold-









Figure 4. Schematic representation of the IL17A effects on CAFs inside PDA. Tumor 
microenvironment composition and organization in the presence (left panel) and absence (right panel) 
of IL17A. The different phenotype acquired by CAFs is highlighted by their different colors (red and 
yellow when in the presence and absence of IL17A, respectively). Straight or curved grey lines 
represent the different orientation and accumulation of collagen fibers in the presence and absence of 
IL17A. Main cytokines/chemokines and factors released by CAFs in the two different scenarios are 
represented by colored dots, as reported at the bottom of each panel. Differentially attracted immune 
cells are represented and described in the legend on the right. 
 
